首页> 外文期刊>Journal of molecular medicine: Official organ of the "Gesellschaft Deutscher Naturforscher und Arzte." >Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent.
【24h】

Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent.

机译:野生型载脂蛋白A-I和载脂蛋白A-I(米兰)基因转移以相似的程度降低了天然和移植性动脉硬化。

获取原文
获取原文并翻译 | 示例
           

摘要

Apolipoprotein (apo) A-I(Milano) is an apo A-I mutant characterized by a cysteine for arginine substitution at position 173. Apo A-I(Milano) carriers have much less atherosclerosis than expected from their low plasma high-density lipoprotein cholesterol levels, suggesting that this mutant may have superior atheroprotective properties. Here, we compare the effect of hepatocyte-directed gene transfer of wild-type human apo A-I and human apo A-I(Milano) on endothelial progenitor cell (EPC) biology and on the progression of native atherosclerosis and allograft vasculopathy in C57BL/6 apo E(-/-) mice. Human apo A-I and apo A-I(Milano) transfer resulted in an equivalent increase of EPC number and function as well as EPC incorporation and endothelial regeneration in allografts and inhibited the progression of native atherosclerosis and allograft vasculopathy to a similar extent. In conclusion, the current head-to-head comparison indicates that human apo A-I(Milano) transfer is not superior compared to wild-type human apo A-I transfer.
机译:载脂蛋白(apo)AI(Milano)是一个apo AI突变体,其特征是在173位的半胱氨酸被精氨酸取代。与低血浆高密度脂蛋白胆固醇水平所预期的相比,载脂蛋白AI(Milano)携带者的动脉粥样硬化要少得多。突变体可能具有优异的抗动脉粥样硬化特性。在这里,我们比较了野生型人类载脂蛋白AI和人类载脂蛋白AI(Milano)的肝细胞定向基因转移对内皮祖细胞(EPC)生物学以及在C57BL / 6 apo E中自然动脉粥样硬化和同种异体血管病变进展的影响(-/-) 老鼠。人载脂蛋白A-I和载脂蛋白A-I(米兰)的转移导致同种异体移植物中EPC数量和功能的同等增加,EPC掺入和内皮再生,并在相似程度上抑制了天然动脉粥样硬化和同种异体血管病的进展。总而言之,当前的正面对比表明,与野生型人类载脂蛋白A-I转移相比,人类载脂蛋白A-I(米兰)转移并不优越。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号